NGM Biopharmaceuticals Stock Forecast, Price & News

NGM Biopharmaceuticals (NASDAQ:NGM) Frequently Asked Questions

Is NGM Biopharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NGM Biopharmaceuticals stock.
View analyst ratings for NGM Biopharmaceuticals or view top-rated stocks.

How has NGM Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NGM shares have increased by 18.0% and is now trading at $18.11.
View which stocks have been most impacted by COVID-19.

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for NGM Biopharmaceuticals.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.03. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 34.43% and a negative net margin of 157.90%.
View NGM Biopharmaceuticals' earnings history.

What price target have analysts set for NGM?

8 brokers have issued 1 year price targets for NGM Biopharmaceuticals' stock. Their forecasts range from $22.00 to $44.00. On average, they anticipate NGM Biopharmaceuticals' share price to reach $35.78 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts' price targets for NGM Biopharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the following people:

• David J. Woodhouse, Chief Executive Officer & Director
• Siobhan Nolan Mangini, CFO & Principal Accounting Officer
• Jin-Long Chen, Director & Chief Scientific Officer
• Hui Tian, Vice President-Research
• Marc Learned, Vice President-Research Operations

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals CEO David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among NGM Biopharmaceuticals' employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NGM Biopharmaceuticals' key competitors?

Some companies that are related to NGM Biopharmaceuticals include Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Perrigo (PRGO), I-Mab (IMAB), Mawson Infrastructure Group (WIZP), Allakos (ALLK), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Zentalis Pharmaceuticals (ZNTL), 23andMe (ME), Arena Pharmaceuticals (ARNA) and ACADIA Pharmaceuticals (ACAD).
View all of NGM's competitors.

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NGM."

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.16%), StepStone Group LP (2.03%), Point72 Asset Management L.P. (1.87%), Geode Capital Management LLC (0.83%), AXA S.A. (0.52%) and Hennion & Walsh Asset Management Inc. (0.36%). Company insiders that own NGM Biopharmaceuticals stock include David J Woodhouse, Group L P Column, Hsiao D Lieu, Hsiao D Lieu, Jin-Long Chen and Peter Svennilson.
View institutional ownership trends for NGM Biopharmaceuticals.

Which institutional investors are selling NGM Biopharmaceuticals stock?

NGM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, SG Americas Securities LLC, Hennion & Walsh Asset Management Inc., Strs Ohio, Nisa Investment Advisors LLC, Squarepoint Ops LLC, New York State Common Retirement Fund, and Lord Abbett & CO. LLC. Company insiders that have sold NGM Biopharmaceuticals company stock in the last year include David J Woodhouse, Hsiao D Lieu, and Jin-Long Chen.
View insider buying and selling activity for NGM Biopharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying NGM Biopharmaceuticals stock?

NGM stock was purchased by a variety of institutional investors in the last quarter, including StepStone Group LP, Point72 Asset Management L.P., Two Sigma Investments LP, Goldman Sachs Group Inc., BlackRock Inc., Citigroup Inc., Two Sigma Advisers LP, and Dimensional Fund Advisors LP. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include Group L P Column, and Peter Svennilson.
View insider buying and selling activity for NGM Biopharmaceuticals or or view top insider-buying stocks.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $18.11.

How much money does NGM Biopharmaceuticals make?

NGM Biopharmaceuticals has a market capitalization of $1.40 billion and generates $87.37 million in revenue each year. The company earns $-102.49 million in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does NGM Biopharmaceuticals have?

NGM Biopharmaceuticals employs 210 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is www.ngmbio.com.

Where are NGM Biopharmaceuticals' headquarters?

NGM Biopharmaceuticals is headquartered at 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact NGM Biopharmaceuticals?

NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 243-5555 or via email at [email protected].